- Home
- LGND vs BLTE Comparison
LGND vs BLTE Comparison
Compare LGND & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | BLTE |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 1992 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LGND | BLTE |
|---|---|---|
| Price | $205.70 | $161.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $243.50 | $156.00 |
| AVG Volume (30 Days) | 210.9K | ★ 227.9K |
| Earning Date | 02-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.76 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $251,233,000.00 | N/A |
| Revenue This Year | $47.71 | N/A |
| Revenue Next Year | $9.77 | N/A |
| P/E Ratio | $80.11 | ★ N/A |
| Revenue Growth | ★ 64.83 | N/A |
| 52 Week Low | $93.58 | $49.00 |
| 52 Week High | $212.49 | $170.25 |
Technical Indicators
Market Signals| Indicator | LGND | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 58.14 |
| Support Level | $188.13 | $148.10 |
| Resistance Level | $199.35 | $163.17 |
| Average True Range (ATR) | 9.00 | 7.81 |
| MACD | 0.55 | -1.14 |
| Stochastic Oscillator | 87.20 | 58.07 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.